MedTrace Logo

Study on the Tolerability, Pharmacodynamics and Pharmacokinetics of GST-HG141 Tablets

NCT04868981 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-06-07

No results posted yet for this study

Summary

To Evaluate the Tolerability, Pharmacodynamics and Pharmacokinetics of GST-HG141 Tablets in Multiple-center, Randomized, Double-blind, Placebo-controlled Multiple-dose, Multiple-administration Study in Patients With Chronic Hepatitis B (CHB)

Conditions

Interventions

DRUG

GST-HG141 tablets

Administrate GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses

DRUG

Matching Placebos for GST-HG141 tablets

Administrate the placebos for GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses

Sponsors & Collaborators

  • Fujian Cosunter Pharmaceutical Co. Ltd

    lead INDUSTRY

Principal Investigators

  • Junqi Niu, PhD · The First Hospital of Jilin University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-31
Primary Completion
2022-02-23
Completion
2022-03-14

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04868981 on ClinicalTrials.gov